{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insulin-therapy-in-type-1-diabetes/background-information/what-is-insulin/","result":{"pageContext":{"chapter":{"id":"457536b7-af83-548a-b54e-8d0edaeafd3f","slug":"what-is-insulin","fullItemName":"What is insulin?","depth":2,"htmlHeader":"<!-- begin field 115aa5c3-a0c9-46e1-9353-359453a8a10e --><h2>What is insulin?</h2><!-- end field 115aa5c3-a0c9-46e1-9353-359453a8a10e -->","summary":"","htmlStringContent":"<!-- begin item 46d269fd-d627-4543-8659-b2cc7f94f5b9 --><!-- begin field 96636398-b4c9-4f0e-b0d7-d4a91778654a --><ul><li><strong>Insulin is a polypeptide hormone secreted by pancreatic beta cells.</strong><ul><li>The role of insulin is to lower blood glucose levels to prevent hyperglycaemia and associated complications, such as microvascular complications (retinopathy, nephropathy, and neuropathy), macrovascular complications (cardiovascular disease, cerebrovascular disease, and peripheral arterial disease), and metabolic complications (diabetic ketoacidosis).</li><li>It achieves this by increasing glucose uptake (by adipose tissue and muscles) and suppressing hepatic glucose release.</li></ul></li><li><strong>The natural profile of insulin secretion consists of two components:</strong><ul><li>Basal insulin — this corresponds to the low and steady level of background insulin in the body. This insulin secretion is necessary to control the glucose that is continuously released from the liver, which is relatively constant although it typically declines slightly during the night and peaks before dawn.</li><li>Meal-time bolus insulin — insulin secretion sharply increases in response to glucose absorbed from food and drink. </li></ul></li><li><strong>In people with type 1 diabetes, </strong>autoimmune destruction of pancreatic beta cells results in absolute insulin deficiency. Consequently, insulin therapy is a medical necessity.<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> for detailed information on managing people with type 1 diabetes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/insulin-therapy-in-type-1-diabetes/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insulin-therapy-in-type-1-diabetes/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 96636398-b4c9-4f0e-b0d7-d4a91778654a --><!-- end item 46d269fd-d627-4543-8659-b2cc7f94f5b9 -->","topic":{"id":"418fc016-0e56-5e3b-b2ea-3927d2911520","topicId":"fea45be3-7039-4e82-a497-8f104e2219fa","topicName":"Insulin therapy in type 1 diabetes","slug":"insulin-therapy-in-type-1-diabetes","lastRevised":"Last revised in July 2020","chapters":[{"id":"954264ab-b538-5bf1-97b7-0f924f8d8cf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3ff43781-7d14-5b7f-afad-bdf21a03a066","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2847fe29-3881-5cdb-a7bc-46613048cf07","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cca9cb48-98c0-532b-be68-7babcbefb124","slug":"changes","fullItemName":"Changes"},{"id":"d93b8dec-544f-532d-902d-66e613ea505d","slug":"update","fullItemName":"Update"}]},{"id":"ec62a12c-2df5-5ba3-83ae-04575a5df833","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bea46ae9-5b5d-5501-8642-95bebd864aa1","slug":"goals","fullItemName":"Goals"},{"id":"637cdedd-d944-52d1-9428-f71dedd59179","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecc1db03-98d4-5682-a7a3-7d52d3da9b84","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ef866cac-6d08-5a10-a858-cbbf60d218e6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2dc6198c-0433-5023-aa1b-6862a4d3ed59","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a289174b-e042-5fce-924a-1f34b54849a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bad524b5-e1b5-52b0-aa55-2cc89cb11660","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"457536b7-af83-548a-b54e-8d0edaeafd3f","slug":"what-is-insulin","fullItemName":"What is insulin?"}]},{"id":"e457b08c-e5c6-5790-ba8c-f88e071da0b0","fullItemName":"Management","slug":"management","subChapters":[{"id":"676c7992-874b-537d-8c19-1f2960b3cc32","slug":"insulin-therapy-type-1-diabetes","fullItemName":"Scenario: Insulin therapy - type 1 diabetes"}]},{"id":"4beb3cd5-7f83-5f1c-9623-cc5e61eae703","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5da0d096-2a12-5776-bc2b-bd37233342e8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8863b2a8-ba84-522f-8b51-20da713ec903","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b16eeb02-30c3-54db-ad00-8543e4b4cef6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"452ae6ee-2e11-57b1-bbed-4515efd11fc8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ead30a9a-3f18-5514-8a77-69d9bf069d3c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d600b94-edf3-51e4-85d9-72002fbf5fc5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6648325a-6d11-5ed7-9bb9-aff9e9d4ee55","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bad524b5-e1b5-52b0-aa55-2cc89cb11660","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}